Dr. Andrew McCollum, MD
What this data tells you about Dr. McCollum
Dr. Andrew McCollum is a hematology & oncology specialist in Dallas, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. McCollum performed 44,235 Medicare services across 2,495 unique beneficiaries.
Between the years covered by Open Payments, Dr. McCollum received a total of $13,371 from 27 pharmaceutical and/or device companies across 87 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. McCollum is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 9,600 | $43 | $136 |
| Anti-nausea injection (fosaprepitant) | 8,850 | $0 | $5 |
| Paclitaxel chemotherapy injection | 5,326 | $0 | $8 |
| Contrast dye for imaging (iodine-based) | 4,707 | $0 | $3 |
| Nivolumab injection (Opdivo) | 4,220 | $24 | $76 |
| Daratumumab injection (Darzalex) | 3,060 | $37 | $126 |
| Dexamethasone injection (steroid) | 1,640 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 900 | $1 | $114 |
| Injection, granisetron hydrochloride, 100 mcg | 750 | $0 | $24 |
| Complete blood count (CBC) with differential | 567 | $8 | $36 |
| Comprehensive metabolic blood panel | 566 | $10 | $64 |
| Blood draw (venipuncture) | 535 | $8 | $20 |
| Office visit, established patient (30-39 min) | 439 | $95 | $368 |
| Injection, leucovorin calcium, per 50 mg | 344 | $3 | $25 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 309 | $23 | $157 |
| Administration of chemotherapy into vein, 1 hour or less | 226 | $104 | $707 |
| Injection, fluorouracil, 500 mg | 222 | $2 | $13 |
| Injection of additional new drug or substance into vein | 221 | $12 | $108 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 209 | $3 | $373 |
| Carcinoembryonic antigen (cea) protein level | 187 | $18 | $99 |
| Injection, carboplatin, 50 mg | 129 | $2 | $300 |
| Injection, magnesium sulfate, per 500 mg | 116 | $1 | $6 |
| Injection, diphenhydramine hcl, up to 50 mg | 87 | $1 | $7 |
| Office visit, established patient, complex (40-54 min) | 83 | $137 | $496 |
| Administration of additional new drug or substance into vein, 1 hour or less | 65 | $52 | $344 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 63 | $49 | $313 |
| Unclassified drugs | 58 | $1 | $8 |
| Injection, zoledronic acid, 1 mg | 56 | $6 | $431 |
| Hospital follow-up visit, moderate complexity | 52 | $61 | $247 |
| Infusion, normal saline solution , 1000 cc | 48 | $2 | $19 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 46 | $58 | $211 |
| Administration of chemotherapy into vein, each additional hour | 46 | $23 | $161 |
| Ct scan of chest with contrast | 42 | $54 | $821 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 42 | $16 | $94 |
| CT scan of abdomen and pelvis with contrast | 41 | $172 | $1,067 |
| Reticulated (young) platelet measurement | 30 | $35 | $143 |
| Microscopic examination for white blood cells with manual cell count | 26 | $4 | $22 |
| Complete blood count (CBC), automated | 26 | $6 | $34 |
| New patient office visit (45-59 min) | 26 | $121 | $565 |
| Irrigation of implanted venous access drug delivery device | 24 | $20 | $114 |
| Chest X-ray, 2 views | 23 | $18 | $61 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 22 | $1,180 | $4,802 |
| Drug injection, under skin or into muscle | 21 | $11 | $96 |
| Administration of chemotherapy into vein using push technique | 21 | $81 | $500 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 21 | $135 | $500 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 20 | $90 | $657 |
| Infusion into a vein for hydration, each additional hour | 18 | $10 | $75 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 18 | $16 | $100 |
| Administration of additional new drug or substance into vein using push technique | 17 | $44 | $289 |
| Hospital follow-up visit, high complexity | 16 | $94 | $357 |
| Ferritin level test (iron stores) | 14 | $13 | $60 |
| Iron level test | 14 | $6 | $27 |
| Iron binding capacity test | 14 | $9 | $35 |
| CT scan of chest, without contrast | 12 | $44 | $686 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
The majority of payments (54%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. McCollum is a mixed practice specialist, with above-average Medicare volume (top 22% in TX), with consulting-driven industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. McCollum experienced with pembrolizumab injection (keytruda)?
Does Dr. McCollum receive payments from pharmaceutical companies?
How do Dr. McCollum's costs compare to other hematology & oncology specialists in Dallas?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology